

1 Urinary extracellular vesicles in healthy individuals: positive correlation between 2 podocyte and tubular vesicles independent of kidney function

3 Liang Wu^{1,2,*}, Carla C. Baan², Derek Reijerkerk², Dennis A. Hesselink², Karin Boer²

4
5 ¹ Department of Nephrology, The First Affiliated Hospital of Shaoyang University, Shaoyang, Hunan, China.

6 ² Erasmus MC Transplant Institute, University Medical Center Rotterdam, Department of Internal Medicine,
7 Division of Nephrology and Transplantation, Rotterdam, the Netherlands.

8
9 Correspondence to: Liang Wu

10 Room No. Na-514, Erasmus MC Transplant Institute, Department of Internal Medicine, University Medical
11 Center Rotterdam Erasmus MC, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. Tel +31
12 0622145029. No Fax. Email: l.wu.1@erasmusmc.nl or 240077670@qq.com. ORCID: 0000-0002-9269-7372

13 14 Abstract

15 Urinary extracellular vesicles (uEVs) are promising non-invasive biomarkers for assessing renal physiology and
16 disease. Focusing specifically on kidney-derived uEVs (kd-uEVs) rather than the overall uEV population may
17 offer a more precise insight into kidney health. However, research distinguishing single kd-uEVs from various
18 nephron segments and their relationship with kidney biology remains limited. Imaging flow cytometry (IFCM)
19 can identify single kd-uEVs by labeling them with CD63 (a uEV marker) in combination with PODXL (a
20 podocyte marker) or AQP2 (a tubular marker). This study investigated the correlations between CD63+ AQP2+
21 or PODXL+ kd-uEVs and kidney function. CD63+ AQP2+ and CD63+ PODXL+ uEVs were detected in urine
22 compared to negative controls, including urine with detergent treatment or isotype staining and reagent-
23 containing PBS. While no significant association was found between CD63+ AQP2+ or PODXL+ uEV
24 concentration and kidney function, a significant correlation was observed between AQP2+ and PODXL+ uEV
25 concentrations ($Rho = 0.789$, $p < 0.001$). This correlation could be explained by the colocalization of AQP2 and
26 PODXL on CD63+ uEVs. In conclusion, our study is the first to demonstrate the colocalization of podocyte and
27 tubular proteins on uEVs.

28
29 **Keywords:** extracellular vesicles; urine, podocyte; renal tubule; cell communication; kidney function

30
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 **Declarations**

32 **Ethical approval**

33 This study including human participants was performed in line with the ethical principles of the Declaration of
34 Helsinki and its later amendments. Approval was granted by the Ethics Committee of Erasmus Medical Center
35 (Ethics approval number: 2018-035).

36

37 **Informed consent to participate and publish**

38 Informed consent regarding participating and publishing data was obtained from all individuals included in this
39 study.

40

41 **Competing interests**

42 Unless otherwise stated, all authors have no conflicts of interest. D.A. Hesselink reports receiving lecture and
43 consulting fees from Astellas Pharma, Chiesi Pharma, MedinCell, Novartis Pharma, and Vifor Pharma and
44 receiving grant support from Astellas Pharma, Bristol-Myers Squibb, and Chiesi Pharma [paid to his institution],
45 without employment or stock ownership at any of these companies, nor does he have patents or patent
46 applications.

47

48 **Data availability statement**

49 The data generated during this study are not publicly available due to concerns regarding participant privacy.
50 Data can be accessed from the corresponding author upon reasonable request. The uEV experimental parameters
51 were submitted to the EV-TRACK knowledgebase (ID: EV240051) and are available at the following URL:
52 <https://evtrack.org/>.

53

54 **Funding**

55 This study was funded by the China Scholarship Council, grant number 202008430154.

56

57 **Acknowledgments**

58 We acknowledge the contribution of Weicheng Xu and Thierry P. P. van den Bosch (EMC) to IFCM and
59 immunohistochemistry experiments. The figure was created on BioRender.com with copyright licenses.

60

61

62 **Introduction**

63 Urinary extracellular vesicles (uEVs) are potential non-invasive biomarkers of renal physiology and disease [1,
64 2]. While the kidney is the primary source, uEVs also derive from the lower urinary tract and the bloodstream
65 [1]. Rather than measuring the overall uEV population, focusing on kidney-derived uEVs (kd-uEVs) may
66 provide a more accurate picture of kidney health. Proteomic analysis of the entire uEVs demonstrated that
67 podocalyxin (PODXL; podocyte marker) and aquaporin 2 (AQP2; tubule/collecting duct marker) are the most
68 abundant kidney-specific proteins [3]. However, research on the discrimination of single kd-uEVs from different
69 nephron segments and their correlation with kidney biology remains limited. Imaging flow cytometry (IFCM)
70 can identify single kd-uEVs by labeling them with CD63 (uEV marker), combined with PODXL or AQP2 [4, 5].
71 This study aimed to explore the correlations between CD63+ AQP2+ or PODXL+ kd-uEVs and sex, age, and
72 kidney function.

73

74 **Methods and Materials**

75 **Patients and urine collection**

76 Spot urine samples were collected from 30 healthy kidney transplant donors at the Erasmus MC, Rotterdam, The
77 Netherlands, between August 2018 and August 2021 (clinical parameters are summarized in **Supplementary**
78 **Table S1**). Urine processing protocols, including centrifugation and addition of a proteinase inhibitor to the
79 supernatant, were described previously [5].

80

81 **Isolation-free labeling of uEVs for IFCM**

82 For the labeling of kidney-derived uEVs, 112 μ L of urine sample underwent staining with 4 μ L of a 30 \times -diluted
83 anti-CD63 monoclonal antibody conjugated with allophycocyanin (CD63-APC, 200 μ g/mL, clone H5C6,
84 Biolegend, San Diego, CA, USA), alongside 4 μ L of a kidney-specific antibody, in a 96-well plate placed in
85 darkness overnight at room temperature. The kidney-specific antibody, either a 15 \times -diluted anti-AQP2
86 conjugated with Alexa Fluor 488 (AQP2-Alexa488, 200 μ g/mL, clone E-2) or a 30 \times -diluted PODXL-Alexa488
87 (200 μ g/mL, clone 3D3), was obtained from Santa Cruz Animal Health (Dallas, TX, USA).

88

89 To explore the colocalization of AQP2 and PODXL on CD63+ uEVs, a triple-staining protocol was executed for
90 IFCM. Herein, 108 μ L of urine sample was stained with 4 μ L of a 15 \times -diluted anti-CD63-eFluor450 (200

91 $\mu\text{g/mL}$, clone H5C6, ThermoFisher Scientific, Waltham, MA, USA), 4 μL of a 15 \times -diluted AQP2-Alexa488,
92 and 4 μL of a 20 \times -diluted PODXL-Alexa647 in darkness overnight at room temperature.

93

94 Before staining, all antibodies were centrifuged at 16,000 g for 10 min. Each stained urine sample was triplicated
95 within the plate, with subsequent analysis employing the median value of the detected uEV concentration. Non-
96 biological background signals, such as antibody aggregates, were identified based on detergent treatment, which
97 lyses phospholipid and lipid particles. Following each IFCM measurement, all labeled samples were incubated
98 with 5 μL of TritonX-100 (final concentration of 0.05%) at room temperature for 30 min before re-measurement.
99 Staining specificity was verified using isotypes conjugating with the same fluorophores and at the same
100 concentrations (**Supplementary Table S2**).

101

102 **Data acquisition and gating strategy for IFCM**

103 The acquisition of Imaging Flow Cytometry (IFCM) data was conducted using an ImageStreamX Mark II
104 instrument (ISx; Cytek Biosciences, Fremont, CA, USA) installed with INSPIRE® software (version
105 200.1.0.765; Cytek Biosciences), following established protocols for analyzing unprocessed urine and plasma [5,
106 6]. The INSPIRE® settings were configured as follows: a flow speed velocity of 40 mm/s, a flow core diameter
107 of 6 μm , 60 \times magnification, and laser wavelengths of 405 nm (channel 01), 488 nm (channel 02), 642 nm
108 (channel 05), and 785 nm for side scatter (SSC) excitation (channel 06). Additionally, bright-field imaging was
109 conducted using channel 04. Fluorescence signals from eFluor450, Alexa488, and APC (or Alexa647) were
110 detected in channels 01, 02, and 05, respectively.

111

112 Quantification of samples was performed using Amnis IDEAS software (version 6.2; Cytek Biosciences) [5, 6].
113 To ensure the quantification of individual urinary extracellular vesicles, a specific gating strategy was employed
114 as previously described [6]. In brief: 1) particles exhibiting SSC intensities ≤ 5279 a.u., corresponding to EVs \leq
115 1200 nm based on calibration, were selected; 2) only singlets were included, while objects with multiple
116 fluorescent spots were excluded; 3) due to the presence of auto-fluorescence (A-F) particles in unprocessed
117 urine, which exhibit positivity in all channels even without antibody staining and cannot be removed by
118 detergent [6], A-F particles showing positivity in an empty channel 03 (no antibody) were excluded from the
119 analysis; 4) gates were set up to identify single, double, or triple-positive uEVs based on unstained, isotype-
120 stained, and single-stained control samples.

121

122 **Immunohistochemistry**

123 The tissue specificity of anti-AQP2 (clone E2, Santa Cruz) and anti-PODXL (clone 3D3, Santa Cruz) antibodies
124 was assessed via immunohistochemistry experiments conducted on formalin-fixed paraffin-embedded (FFPE)
125 sections obtained from residual peritumoral tissue from nephrectomies performed for oncological purposes
126 (**Supplementary Fig. S1**). Immunohistochemistry Chromogenic multiplex (cmIHC) analysis was conducted
127 using an automated cmIHC system, specifically the Ventana Benchmark DiscoverAy ULTRA (Ventana Medical
128 Systems Inc., Oro Valley, AZ, USA).

129
130 In summary, 4 μm thick tissue sections were stained following deparaffinization and heat-induced antigen
131 retrieval with CC1 (#950-224, Ventana) for 32 minutes. A 4000 \times dilution of anti-podocalyxin ligand 1 was
132 incubated at 37°C for 32 minutes, followed by treatment with omnimap anti-mouse HRP (#760-4310, Ventana)
133 and detection with purple (#760-299, Ventana) for 32 minutes. An antibody denaturation step was then
134 performed with CC2 (#950-123, Ventana) at 100°C for 20 minutes. Subsequently, incubation with a 100 \times
135 dilution of anti-AQP2 was conducted at 37°C for 32 minutes, followed by mouse-NP and anti-NP-AP (#760-
136 4816 and #760-4827, Ventana) and detection with the Yellow AP kit (#760-239, Ventana). Counterstaining was
137 performed with hematoxylin II for 4 minutes, followed by a blue coloring reagent for an additional 4 minutes, as
138 per the manufacturer's instructions (Ventana). Finally, slides were scanned using the Hamamatsu Nanozoomer
139 (Hamamatsu Photonics, Hamamatsu, Japan).

140
141 Reagent-containing phosphate-buffered saline (PBS), detergent-treated urine, and isotype-stained urine were
142 used to validate the uEV measurement [1]. As recommended by the International Society for Extracellular
143 Vesicles [1], urine dilution was normalized by calculating the concentration ratio of uEVs to urinary creatinine
144 (UCr) measured with CRE2U, ACN 8152 (Roche Diagnostics Nederland BV).

145 146 **Statistical analysis**

147 Data were presented as median [quartile 1 – quartile 3; Q1 – Q3]. Correlations between sex, age, eGFR, and
148 UCr-normalized AQP2+ or PODXL+ uEV concentrations were examined using Spearman's correlation. Linear
149 regression analyses were performed between eGFR, log-transformed UCr-normalized AQP2+ uEV, and
150 PODXL+ uEV concentrations. A schematic overview of sample collection, processing, and staining is illustrated
151 in **Supplementary Fig. S2**.

152

153 Results

154 CD63+ AQP2+ uEVs (**Fig. 1a**) and CD63+ PODXL+ uEVs (**Fig. 1b**) were clearly present in urine compared to
155 the negative controls, including detergent treatment, reagent-containing PBS, and isotype staining (**Fig. 1c – 1g**).
156 The medians of UCr-normalized CD63+ AQP2+ uEV and CD63+ PODXL+ uEV concentrations were 3.5 [Q1 –
157 Q3: 0.8 – 6.8] $\times 10^4$ objects/ μmol and 3.6 [1.2 – 7.7] $\times 10^4$ objects/ μmol , respectively, with less than 20% of
158 these uEVs measured in detergent-treated or isotype-stained urine (**Fig. 1h**; all p values < 0.001). With the
159 presence of detergent, 40 – 90% of objects stained negative for CD63 but positive for AQP2 or PODXL (**Fig. 1c**,
160 **1d**). In addition, compared to urine (**Fig. 1a, 1b**), reagent-containing PBS contained 10% of CD63-negative and
161 AQP2/PODXL-positive backgrounds (**Fig. 1e, 1f**), indicating free antibody aggregations rather than biological
162 uEVs. No significant association was observed between CD63+ AQP2+ or PODXL+ uEV concentration and
163 sex, age, or eGFR, but a significant correlation was found between AQP2+ and PODXL+ uEV concentrations
164 ($Rho = 0.789$, $p < 0.001$; **Fig. 1i**). Regression analyses were used to visualize these correlations, which also
165 demonstrated weak associations between eGFR and AQP2+ uEV concentrations ($R^2 = 0.00$, $p = 0.98$; **Fig. 1j**) or
166 between eGFR and PODXL+ uEV concentrations ($R^2 = 0.04$, $p = 0.30$; **Fig. 1k**). However, a higher level of
167 PODXL+ uEVs was significantly associated with a higher AQP2+ uEV level ($R^2 = 0.64$, $p < 0.001$; **Fig. 1l**). To
168 explore whether AQP2 colocalizes with PODXL on the CD63+ uEV surface, we performed CD63-AQP2-
169 PODXL triple staining. About 50% of the CD63+ uEVs expressing PODXL were triple-positive and expressed
170 AQP2 (**Fig. 1m**). Representative images for AQP2+ PODXL+ CD63+ uEVs are displayed in **Fig. 1n**. The
171 specific colocalization of AQP2 and PODXL on CD63+ uEVs was strengthened by the negative controls and
172 rare AQP2 and PODXL double-positivity measured in CD63- events (**Supplementary Fig. S3**). The median of
173 UCr-normalized triple-positive uEV concentration was 6.4 [4.0 – 14.9] $\times 10^3$ objects/ μmol , significantly higher
174 than in controls with detergent treatment ($p = 0.004$) or isotype staining ($p < 0.001$; $N = 10$; **Fig. 1o**).

175

176 Discussion

177 This study investigated the association between kidney biology and podocyte-derived PODXL+ uEVs as well as
178 tubule/collecting duct-derived AQP2+ uEVs. There was no correlation between these kd-uEV levels and sex,
179 age, or eGFR. Despite the substantial anatomical distance between podocytes and collecting duct cells, a
180 significant correlation was found between the uEVs expressing AQP2 and PODXL, which can be explained by
181 the partial colocalization of these proteins on uEVs. Collecting duct cells are active in absorbing podocyte-
182 derived uEVs [7]. Endocytosis is a typical way to uptake external vesicles, allowing the endosomal system to

183 package native molecules and release exosomes, a distinctive uEV subtype marked by CD63 expression [8]. This
184 procedure can lead to vesicle membrane reversion or the presence of inside-out proteins on its surface [9]. Our
185 AQP2 antibody targets its intracellular domain, which typically faces the lumen of vesicles rather than the
186 exterior environment [10]. Therefore, the presence of uEVs with exterior AQP2 further suggests their endosomal
187 origin [10]. Our study provides evidence of EV-mediated protein delivery in the human nephron, which gives
188 new insights into the intra-nephron cross-talk and kidney biology.

189

190 The limitation is that other kidney-specific markers on uEVs, such as tubular co-transporters, were not measured.
191 Characterization of more markers can help understand the role of EVs in kidney physiology, but our study, for
192 the first time, demonstrates the colocalization of podocyte and tubular proteins on uEVs. Further investigations
193 are needed to confirm these findings and fully explore uEV-mediated communication in nephron health and
194 disease.

195

196 **Conclusion**

197 The release of PODXL+ or AQP2+ CD63+ kd-uEVs is not correlated with kidney function. The correlation
198 between these two uEV populations can be explained by the colocalization of PODXL and AQP2 on CD63+
199 uEVs.

200

201 **Supplementary file**

202 This study contains a supplementary file.

203

204 **Authors' contributions:**

205 Conceptualization: [Liang Wu], [Carla C. Baan], [Karin Boer]; Methodology: [Liang Wu], [Derek Reijerkerk];
206 Formal analysis and investigation: [Liang Wu]; Writing - original draft preparation: [Liang Wu]; Writing -
207 review and editing: [Liang Wu], [Carla C. Baan], [Karin Boer], [Derek Reijerkerk], [Dennis A. Hesselink];
208 Funding acquisition: [Liang Wu], [Carla C. Baan], [Karin Boer]; Resources: [Carla C. Baan], [Karin Boer],
209 [Dennis A. Hesselink]; Supervision: [Carla C. Baan], [Karin Boer], [Dennis A. Hesselink].

210


211

212 **References:**

- 213 1. Erdbrügger U, Blijdorp CJ, Bijnsdorp I V., et al (2021) Urinary extracellular vesicles: A position paper
214 by the Urine Task Force of the International Society for Extracellular Vesicles. *J Extracell Vesicles*
215 10:e12093. <https://doi.org/10.1002/jev2.12093>
- 216 2. Perez-Hernandez J, Martinez-Arroyo O, Ortega A, et al (2021) Urinary exosomal miR-146a as a marker
217 of albuminuria, activity changes and disease flares in lupus nephritis. *J Nephrol* 34:1157–1167.
218 <https://doi.org/10.1007/s40620-020-00832-y>
- 219 3. Braun F, Rinschen M, Buchner D, et al (2020) The proteomic landscape of small urinary extracellular
220 vesicles during kidney transplantation. *J Extracell Vesicles* 10:e12026.
221 <https://doi.org/10.1002/jev2.12026>
- 222 4. Musante L, Bontha SV, La Salvia S, et al (2020) Rigorous characterization of urinary extracellular
223 vesicles (uEVs) in the low centrifugation pellet - a neglected source for uEVs. *Sci Rep* 10:1–14.
224 <https://doi.org/10.1038/s41598-020-60619-w>
- 225 5. Wu L, van Heugten MH, van den Bosch TP, et al (2024) Polarized HLA Class I Expression on Renal
226 Tubules Hinders the Detection of Donor-Specific Urinary Extracellular Vesicles. *Int J Nanomedicine*
227 19:3497–3511. <https://doi.org/10.2147/IJN.S446525>
- 228 6. Wu L, Woud WW, Baan CC, et al (2023) Isolation-free measurement of single urinary extracellular
229 vesicles by imaging flow cytometry. *Nanomedicine Nanotechnology, Biol Med* 48:.
230 <https://doi.org/10.1016/j.nano.2022.102638>
- 231 7. Gildea JJ, Seaton JE, Victor KG, et al (2014) Exosomal transfer from human renal proximal tubule cells
232 to distal tubule and collecting duct cells. *Clin Biochem* 47:89–94.
233 <https://doi.org/10.1016/j.clinbiochem.2014.06.018>
- 234 8. Mathieu M, Névo N, Jouve M, et al (2021) Specificities of exosome versus small ectosome secretion
235 revealed by live intracellular tracking of CD63 and CD9. *Nat Commun* 12:1–18.
236 <https://doi.org/10.1038/s41467-021-24384-2>
- 237 9. Cvjetkovic A, Jang SC, Konečná B, et al (2016) Detailed Analysis of Protein Topology of Extracellular
238 Vesicles-Evidence of Unconventional Membrane Protein Orientation. *Sci Rep* 6:1–12.
239 <https://doi.org/10.1038/srep36338>
- 240 10. Blijdorp CJ, Tutakhel OAZ, Hartjes TA, et al (2021) Comparing approaches to normalize, quantify, and
241 characterize urinary extracellular vesicles. *J Am Soc Nephrol* 32:1210–1226.
242 <https://doi.org/10.1681/ASN.2020081142>

243

244



245 **Fig. 1** Measurement of kidney-derived urinary extracellular vesicles using IFCM. **a – g** Representative
 246 scatterplots of uEV in IFCM. Urine is stained by CD63-APC combined with AQP2-Alexa488 (**a**) or PODXL-
 247 Alexa488 (**b**). **c, d** Stained urine was treated with detergent. PBS with CD63-APC and AQP2-Alexa488 (**e**) or
 248 PODXL-Alexa488 (**f**). **g** Urine is labeled by IgG-APC and IgG-Alexa488. These scatterplots show CD63-APC
 249 single-positives in the “APC+” gate, AQP2 or PODXL-Alexa488 single-positives in “Alexa488+”, and double-
 250 positives in “++”. Each gate’s name denotes the count and the percentage of gated objects. **h** A summary of

251 urine samples showing UCr-normalized CD63+ AQP2+ or CD63+ PODXL+ uEV concentrations with controls
252 of detergent treatment and isotype staining. **i** A Spearman test showing correlations among sex, age, eGFR, and
253 UCr normalized kd-uEV levels. The Rho value is presented in each cell to demonstrate the correlation between
254 the corresponding X- and Y-axis parameters. A scale bar of the Rho value is presented on the right of the
255 heatmap. The red and blue colors depict positive and negative correlations, respectively. **j – l** Linear regression
256 analyses between eGFR and AQP2+ uEV concentration (**j**), eGFR and PODXL+ uEV concentration (**k**), and
257 between AQP2+ and PODXL+ uEV concentrations (**l**). The concentrations of uEVs are normalized by urine
258 creatinine and log-transferred. **m** The characterization of AQP2 or PODXL positiveness on the CD63+ uEVs.
259 All dots are CD63+. The red gate denotes PODXL positivity, the green gate shows AQP2 expression, and the
260 purple gate double-positive (“+++”) signal for AQP2 and PODXL. Each gate’s name includes the gated count and
261 percentage. **n** The representative images for AQP2+ PODXL+ CD63+ uEVs, AQP2+ PODXL- CD63+ uEVs,
262 and PODXL+ AQP2- CD63+ uEVs. The object number is listed on the left of each image. **o** A summary of UCr-
263 normalized AQP2-PODXL-CD63 triple-positive uEV concentrations measured in urine, urine with detergent
264 treatment, and isotype staining. **Marks:** **, $p < 0.01$; ***, $p < 0.001$.

265
266 *AQP2* aquaporin 2; *D* detergent-treated control; *eGFR* estimated glomerular filtration rate; *IFCM* imaging flow
267 cytometry; *ISO* isotype-staining control; *PODXL* podocalyxin; *UCr* urine creatinine.
268